Patent protects ready to use liquid formulation of GerlinC which improves efficiency and focus for surgeons, resulting in a 10-minute procedure Robust IP portfolio includes 35 issued patents to date worldwide GerlinC is in a pivotal FDA trial, has received regulatory approval in the EU, and is the world's first off-the-shelf regenerative treatment for knee cartilage repair HERZLIYA, IL / ACCESS Newswire / December 18, 2025 / Regentis Biomaterials Ltd., ("Regentis" or the "Company") (NYSE American:RGNT), a r ...